Journal Mobile Options
Table of Contents
Vol. 69, No. 4, 2007
Issue release date: June 2007
ORL 2007;69:218–225

Downregulation of Fanconi Anemia Genes in Sporadic Head and Neck Squamous Cell Carcinoma

Wreesmann V.B. · Estilo C. · Eisele D.W. · Singh B. · Wang S.J.
aDepartment of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, Calif., and bHead and Neck Service, Memorial Sloan-Kettering Cancer Center, New York, N.Y., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: Much of our understanding of human cancer has come from studies of the hereditary cancer predisposition syndromes. Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA crosslinking agents, progressive bone marrow failure, and cancer predisposition to solid malignancies, especially head and neck squamous cell carcinoma (HNSCC). Since FA pathway-deficient cells are hypersensitive to DNA crosslinking chemotherapy agents, the presence of somatic FA gene inactivation in sporadic cancers may be of clinical interest. This study sought to determine the frequency of FA gene downregulation in sporadic HNSCC. Methods: The expression of the FA genes FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCJ, FANCL and FANCM in 11 HNSCC cell lines and 49 tongue carcinoma samples was studied with quantitative real-time polymerase chain reaction. Results: Downregulation of at least one FA gene was observed in 3 of 11 HNSCC cell lines and 66% of tongue carcinoma samples. FANCB, FANCF, FANCJ and FANCM were most commonly affected by downregulation, whereas downregulation of FANCA, FANCE and FANCD2 was rare. Conclusion: Our data suggest that downregulation of FA genes is common in sporadic HNSCC. The clinical implications of this finding merit further study.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Taniguchi T, D’Andrea AD: Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006;107:4223–4233.
  2. Mirchandani KD, D’Andrea AD: The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. Exp Cell Res 2006;312:2647–2653.
  3. Kutler DI, Singh B, Satagopan J, et al: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003;101:1249–1256.
  4. Kutler DI, Auerbach AD, Satagopan J, et al: High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003;129:106–112.
  5. Kutler DI, Wreesmann VB, Goberdhan A, et al: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003;95:1718–1721.
  6. Taniguchi T, Tischkowitz M, Ameziane N, et al: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568–574.
  7. van der Heijden MS, Brody JR, Dezentje DA, et al: In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005;11:7508–7515.
  8. Chirnomas D, Taniguchi T, de la Vega M, et al: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006;5:952–961.
  9. Singh B, Gogineni SK, Sacks PG, et al: Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res 2001;61:4506–4513.
  10. Wang SJ, Bourguignon LY: Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:19–24.
  11. Ishisaki A, Oida S, Momose F, et al: Identification and characterization of autocrine-motility-factor-like activity in oral squamous-cell-carcinoma cells. Int J Cancer 1994;59:783–788.
  12. Wagner W, Ansorge A, Wirkner U, et al: Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis. Blood 2004;104:675–686.
  13. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996;87:159–170.
  14. Wreesmann VB, Singh B: Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. J Oral Pathol Med 2005;34:449–459.
  15. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004;10:789–799.
  16. Tremblay S, Pintor dos Reis P, Bradley G, et al: Young patients with oral squamous cell carcinoma: study of the involvement of GSTP1 and deregulation of the Fanconi anemia genes. Arch Otolaryngol Head Neck Surg 2006;132:958–966.
  17. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23:1000–1004.
  18. Tischkowitz MD, Morgan NV, Grimwade D, et al: Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 2004;18:420–425.
  19. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE: Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63:2585–2588.
  20. D’Andrea AD: The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003;2:290–292.
  21. D’Andrea AD, Grompe M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23–34.
  22. Wreesmann VB, Shi W, Thaler HT, et al: Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol 2004;22:3965–3972.
  23. Wreesmann VB, Sieczka EM, Socci ND, et al: Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 2004;64:3780–3789.
  24. van der Heijden MS, Brody JR, Gallmeier E, et al: Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004;165:651–657.
  25. van Zeeburg HJ, Snijders PJ, Pals G, et al: Generation and molecular characterization of head and neck squamous cell lines of Fanconi anemia patients. Cancer Res 2005;65:1271–1276.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50